Can focused ultrasound gene therapy improve outcomes for glioblastoma based on preclinical studies?

Focused ultrasound (FUS) is a noninvasive technique that can temporarily open the blood-brain barrier, allowing gene therapies to reach brain tumors. In glioblastoma, a highly aggressive brain cancer, delivering genetic treatments past this barrier is a major challenge. Preclinical studies in animal models suggest that combining FUS with gene therapy may improve outcomes by increasing gene delivery and shrinking tumors.

What the research says

A meta-analysis of nine preclinical studies found that FUS-mediated gene therapy significantly enhanced gene expression in brain tissue (pooled effect size 6.34), reduced tumor volume (pooled effect size 4.03), and improved survival in orthotopic glioblastoma models ³. The delivered genes included therapeutic transgenes like MDA-7/IL-24, HSV-TK, shBirc5, and CRISPR/Cas9, using viral, non-viral, nanoparticle, and exosome-based vectors ³. FUS parameters varied, but the overall results support its potential to overcome the blood-brain barrier ³. Other research highlights that techniques to overcome the BBB for targeted delivery are being tested in clinical trials for recurrent glioblastoma ⁹, and nanotechnology platforms are being developed to enhance delivery of gene therapies ¹⁰. However, these findings are from animal models, and human trials are needed to confirm safety and efficacy.

What to ask your doctor

• Are there any clinical trials testing focused ultrasound gene therapy for glioblastoma that I might be eligible for?
• What are the potential risks and benefits of focused ultrasound compared to other BBB-opening techniques?
• How do preclinical results from animal studies typically translate to human glioblastoma treatments?
• Could focused ultrasound be combined with other therapies I am currently receiving?
• What is the current status of focused ultrasound technology in glioblastoma care at this center?